Co-Diagnostics shares are trading higher after the company announced continued progress in its Ebola PCR development program with joint venture CoSara Diagnostics.

Benzinga Newsdesk www.benzinga.com Positive 95.4%

Neg 0% Neu 0% Pos 95.4%

Comments

No comments yet. Be the first!